## RESEARCH

## **Open Access**

# The risk of anaphylaxis behind authorized COVID-19 vaccines: a meta-analysis



Marharyta Sobczak<sup>®</sup> and Rafał Pawliczak<sup>\*</sup>

## Abstract

**Background:** A serious allergic reaction that may occur in response to medical products is anaphylaxis, which potentially can lead to anaphylactic shock. In the light of recent COVID-19 pandemic, much public attention had been paid to the severe allergic reactions occurring after COVID-19 vaccination. Therefore, in our study we would like to investigate the risk of authorized COVID-19 vaccines to induce anaphylactic reaction, anaphylactoid reaction, anaphylactic shock and anaphylactoid shock.

**Methods:** We searched databases, such as PubMed, Web of Science and Embase and found eight articles about the incidence of anaphylactic and anaphylactoid reactions. Also, we used data from four databases from Canada, the U.S., the European Union and the United Kingdom. To calculate effect sizes, we used random effects model with inverse variance method. The risk ratio with 95% confidence interval were used for dichotomous outcomes. Statistical analysis was prepared in R. Results were considered statistically significant at p < 0.05.

**Results:** The most cases of anaphylactic reaction, anaphylactoid reaction, anaphylactic shock and anaphylactoid shock were reported in female aged 18–85 years after BNT162b2 vaccine according to data from the EU. Analyzed COVID-19 vaccines can cause the anaphylaxis/anaphylactic reaction with risk of 106.99 (95% CI [39.95; 286.57], p < 0.0001,  $l^2 = 59\%$ ), whereas the anaphylactoid reaction, anaphylactic and anaphylactoid shocks with risk of 113.3 (95% CI [28.11; 456.53], p < 0.0001), 344.2 (95% CI [85.77; 1381.39], p < 0.0001), 14.9, 95% CI [1.96; 112.79], p = 0.009), respectively.

**Conclusions:** Our meta-analysis shows that the risk of anaphylactic reaction, anaphylactoid reaction, anaphylactic shock and anaphylactoid shock do not occur only after mRNA COVID-19 vaccines. Therefore, vaccination centers should be prepared to render assistance in the event of a reaction in all cases.

Keywords: COVID-19, Vaccines, Anaphylaxis, Coronavirus infection, SARS-CoV-2, Meta-analysis

## Introduction

The first identified case of COVID-19 occurred in Wuhan in December 2019. Spreading around the world and infected 114 countries in March 2020, COVID-19 was classified as a pandemic [1]. According to WHO COVID-19 dashboard [2], around 245.37 million cases of COVID-19 infections have been reported on October

\*Correspondence: rafal.pawliczak@csk.umed.lodz.pl Department of Immunopathology, Faculty of Medicine, Division of Biomedical Science, Medical University of Lodz, St. Zeligowskiego 7/9, 90-752 Lodz, Poland 29, 2021 with around 4.98 million deaths. An important part of fighting a pandemic is finding an effective yet safe vaccine. There are different types of COVID-19 vaccines in development stages. On October 29, 2021 around 6.84 billion doses of COVID-19 vaccines have been distributed over the world [2]; whereas on October 30, 2021 there were 1053 clinical studies of COVID-19 vaccines [3].

In the European Union (EU), there are four COVID-19 vaccines authorized for use: BNT162b2, mRNA-1273, ChAdOx1 nCoV-19 and Ad26.COV2.S [4]. BNT162b2 and mRNA-1273 are the lipid nanoparticle-formulated



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

mRNA vaccines that encoding SARS-CoV-2 spike glycoprotein with proline mutation in two sites [5-7]. These vaccines were authorized for use in human subjects by U.S. FDA (Food and Drug Administration) in December 2020: December 11, 2020 for BNT162b2 vaccine and December 18, 2020 for mRNA-1273 vaccine, respectively [8]. In contrast, the authorization approval of these vaccines in the European Union came a little later: December 21, 2020 for BNT162b2 vaccine and January 6, 2021 for mRNA-1273 vaccine [4]. The results of phase 2/3 of randomized clinical trial of BNT162b2 vaccine showed that this vaccine has 95% efficiency against COVID-19 after full vaccination with two doses in participants older than 16 years [7]. Similar results showed the phase 3 randomized clinical trial of mRNA-1273 vaccine-94.1% efficiency in participants older than 18 years [9]. In addition, the safety and efficiency of BNT162b2 vaccine were studied on adolescents at the age of 12 to 15 years and demonstrated 100% vaccine efficacy [5]. Therefore, the BNT162b2 vaccine is currently recommended for use in adolescents aged 12-15 years according to U.S. FDA emergency use authorization from May 10, 2021 [8]. In contrast, the other two vaccines (ChAdOx1 nCoV-19 and Ad26.COV2.S) have been authorized in the EU on January 29, 2021 and March 11, 2021, respectively [4]. These vaccines include a viral vector that is unable to replicate and encodes SARS-CoV-2 spike glycoprotein. ChAdOx1 nCoV-19 vaccine contains chimpanzee adenovirus vector, while Ad26.COV2.S contains human adenovirus serotype 26 [10-13]. As of February 27, 2021 Ad26.COV2.S vaccine has been approved by the U.S. FDA [8]. The randomized clinical trial in phase 3 showed the efficiency of this single dose vaccine at level 67% after 14 days of vaccination and 66% after 28 days of vaccination [13]. An interim analysis of four ChAdOx1 nCoV-19 vaccine randomized clinical trials showed the vaccine efficiency equals 70.4% after full vaccination with two doses [14]. In addition, an exploratory analysis of randomized clinical trial in phase 2/3 showed the efficiency of vaccine was 81.5% against non-B.1.1.7 variants of COVID-19 and 70.4% against B.1.1.7 variant [15].

An important aspect of the new vaccines is their safety. While in usual situation it takes more time to produce new vaccines, the process of developing and producing COVID-19 vaccines was accelerated due to urgent need to fight the pandemic [16]. Potentially all vaccines can cause anaphylaxis [17]. Anaphylaxis is severe, systemic, immediate allergic reaction. There are different types of anaphylaxis. The first one is uniphasic, which occurs the most commonly and very quickly—within 30–60 min. The second one is biphasic, which recurs after the first symptoms have disappeared without re-exposure to the trigger. And the last one is persistent, which can last

several days or even weeks [18]. In 2004, Brown [19] developed new system grading of anaphylaxis, defining the severe anaphylaxis as failure of respiratory or cardiovascular system. This grading consists of three levels: mild pertaining to skin and subcutaneous tissue, moderate concerns the gastrointestinal, cardiovascular or respiratory systems, and severe, which includes neurologic compromise, hypoxia or hypertension. Therefore, assessment of the risk of anaphylaxis after vaccination is an crucial point in vaccine safety research [17]. The typical symptoms of anaphylaxis are urticaria or angioedema, bronchospasm and hypotension [20]. During anaphylaxis after exposure to allergen, mast cells or basophils produce inflammatory immune mediators caused by IgE (immunoglobulin E) binding to high affinity receptors FceRI leading to crosslinking of receptors and activation of these cells. Produced mediators, such as histamine, proteases and leukotrienes, prostaglandins can lead to bronchial smooth muscle contraction, vasodilation, as well as increased mucus production and vascular permeability [20-22]. Besides anaphylactic reaction, there is anaphylactoid reaction that has similar symptoms and treatment, but other mechanisms consisting of the complement activation or activation of bradykinin cascade and mast cells or basophils direct activation [20, 22]. Therefore, in our study, we would like to compare COVID-19, up-to-date registered, vaccines in terms of incidence of anaphylactic reaction, anaphylactoid reaction, anaphylactic shock, and anaphylactoid shock after vaccine administration. Our study showed that anaphylaxis may occur after administration of either mRNA- or virus-based vaccine. Interestingly, the frequency of anaphylaxis among the vaccinated group is higher in female patients which may suggest potential involvement of hormonal regulation in origin of anaphylaxis.

## Methods

## Search strategy, data search and extraction

For this meta-analysis, databases, such as Embase, Pub-Med and Web of Science were searched to find literature published before October 14, 2021 using the following search strategy: ((((COVID-19) OR (coronavirus infection)) OR (SARS-CoV-2)) AND ((vaccine) OR (vaccination))) AND (((((anaphylaxis) OR (anaphylactic reaction)) OR (anaphylactic shock)) OR (anaphylactoid reaction)) OR (anaphylactoid shock)). We included all reports and studies published in English about anaphylaxis or anaphylactoid incidents caused by authorized COVID-19 vaccines, such as BNT162b2, mRNA-1273, ChAdOx1 nCoV-19 and Ad26.COV2.S. Additionally, we used data from EudraVigilance–European database of suspected adverse drug reaction reports [23] about the number of reported cases of anaphylactic reaction, anaphylactoid reaction, anaphylactic shock, and anaphylactoid shock after COVID-19 vaccination with vaccines authorized in the European Union: BNT162b2, mRNA-1273, ChAdOx1 nCoV-19 and Ad26.COV2.S, up to October 9, 2021. Information about the number of doses of the foregoing COVID-19 vaccines administered to EU/EEA countries downloaded from COVID-19 Vaccine Tracker from *European Centre for Disease Prevention and Control* [24] as of 41 week of 2021 year (October 10, 2021). Also, we used data from *CDC—Centers for Disease Control and Prevention* [25] (up to October 8, 2021), *Public Health Agency of Canada* [26] (up to October 1, 2021) and *Medicines and Healthcare products Regulatory Agency* [27] (up to October 6, 2021). Literature search was prepared according to PRISMA flow diagram [28].

## Statistical analysis

The statistical analysis was prepared using R version 4.0.5. Additionally, we used GraphPad Prism 8.0.2 for graph preparation. To compare the cases of anaphylaxis caused by COVID-19 vaccines with absent of vaccination, the risk ratio (RR) with 95% confidence interval (CI) were used for dichotomous outcomes. We used data about number of anaphylactic reactions, anaphylactoid reactions, anaphylactic shocks, and anaphylactoid shocks per administrated doses of particular COVID-19 vaccines. If such data were not available, we used the rate of anaphylactic reactions, anaphylactoid reactions, anaphylactic shocks, and anaphylactoid shocks per million administrated doses of particular COVID-19 vaccines. We assumed that the control group would be unvaccinated individuals with an anaphylactic reaction, anaphylactoid reaction, anaphylactic shock, and anaphylactoid, which prompted by COVID-19 vaccines at rate of 0. Random effects model using inverse variance method was used to calculate effect sizes. I<sup>2</sup> statistics was used to evaluate the heterogeneity of studies:  $I^2 < 40\%$  may not be important;  $30\% < I^2 < 60\%$  means moderate heterogeneity;  $50\% < I^2 < 90\%$  means substantial heterogeneity;  $I^2 > 75\%$ means considerable heterogeneity [29]. Results of this meta-analysis were considered statistically significant at p < 0.05.

## Results

After electronic searching, 241 non-duplicated records were identified as shown on Fig. 1. Next, we excluded 215 records after titles and abstracts screening and 18 after full-text screening. Finally, our meta-analysis contains 2 research letters from Japan [30] and U.S. [31], an interim analysis from 8 data-contributing health plans in the U.S. [32], and 5 reports from U.S. [33–35], South Korea [36] and Japan [37]. Additionally, we used data from 4

databases that contain information about anaphylaxis and anaphylactoid reaction incidence after COVID-19 vaccination of population in the European Union [23], U.S. [25], Canada [26] and United Kingdom [27].

## Gender association with anaphylaxis after COVID-19 vaccines

Based on data from *EudraVigilance–European database* of suspected adverse drug reaction reports [23], we indicated that anaphylactic reactions, anaphylactoid reactions, anaphylactic shock, and anaphylactoid shock may occur after all approved COVID-19 vaccines. Of these, most cases of these reactions were reported in female aged 18–85 years after vaccination with BNT162b2 vaccine, as shown on Fig. 2.

## Anaphylaxis or anaphylactic reactions after COVID-19 vaccines


In this analysis, we used 6 articles [30-35] and 4 databases [23, 25-27] that indicates the number of anaphylaxis or anaphylactic reactions after COVID-19 vaccination. Because of high heterogeneity, we performed the subgroup analysis and found that the overall risk of anaphylaxis or anaphylactic reaction after vaccination with authorized COVID-19 vaccines was 106.99 (95% CI [39.95; 286.57], p<0.0001, I<sup>2</sup>=59%) with substantial heterogeneity, as shown on Fig. 3. Moreover, the highest risk of anaphylaxis or anaphylactic incidences was after adenovirus-vector vaccine Ad26.COV2.S and equals 209 (95% CI [29.3; 1490.67], I<sup>2</sup>=0%) without heterogeneity, while the lowest risk was 62.89 (95% CI [14.08; 280.84], I<sup>2</sup>=55%) with substantial heterogeneity after mRNA vaccine mRNA-1273.

## Anaphylaxis including anaphylactoid reactions after COVID-19 vaccines

A few reports [36, 37] and database [27] reported the cases of anaphylaxis and anaphylactoid reactions after BNT162b and ChAdOx1 nCoV-19 vaccines. As shown Fig. 4, the risk of anaphylaxis and anaphylactoid reactions caused by these vaccines was 54.94 (95% CI [15.65; 192.83], p < 0.0001,  $I^2 = 0\%$ ).

## Anaphylactic shock, anaphylactoid reaction and anaphylactoid shock after COVID-19 vaccines


Additionally, we analyzed the incidents of anaphylactic shock, anaphylactoid reaction and anaphylactoid shock after COVID-19 vaccines authorized in the EU based on data from *EudraVigilance–European database of suspected adverse drug reaction reports* [23]. COVID-19 vaccines caused more anaphylactic shock (RR=344.2, 95% CI [85.77; 1381.39], p < 0.0001), anaphylactoid reaction



(RR = 113.3, 95% CI [28.11; 456.53], p < 0.0001) and anaphylactoid shock (RR = 14.9, 95% CI [1.96; 112.79], p = 0.009) without heterogeneity (Fig. 5).

## Discussion


Our meta-analysis shows that after vaccination with COVID-19 vaccines, there is a risk of incidence of anaphylactic reaction, anaphylactoid reaction, anaphylactic shock, and anaphylactoid shock. In the EU, the most numbers of these reactions were reported for vaccinated people at age between 18 and 85 years, and the least numbers in vaccinated cohort at age less than 18 years and above than 85 years. Moreover, the most numbers of anaphylaxis was reported in vaccinated females compared to males at age between 18 and 85 years. Interestingly, in this cohort of females, the most numbers of reactions were reported after administration of BNT162b2 vaccine, which can be explained by the predominant number of administrated doses of this vaccine compared to other vaccines [24]. It can suggest that gender plays an important role in anaphylaxis. In general, studies showed that females have more predisposition to drug allergy, for example to penicillin. However, this association has not been observed in children. This can be explained by sex hormones. Estrogen can enhance activity of endothelial nitric oxide synthase, which was




observed in study carried out on mice. This led to elevation of the vascular permeability as well as the severity of anaphylaxis [38, 39]. On the other hand, progesterone can inhibit production of histamine from mast cells [39]. Similar results in the subject of predominant of female cases of anaphylaxis in adults were observed in study, in which rates of anaphylaxis after vaccination in period between January 1, 2009 and December 31, 2011 were analyzed [17].

Among analyzed vaccines, Ad26.COV2.S vaccine had the highest risk of anaphylaxis/ anaphylactic reaction in the U.S. and EU. Moreover, in the EU, cases of anaphylactic shock and anaphylactoid reaction were reported, but the risk of these was the lowest among analyzed vaccines. Other virus vector vaccine ChAdOx1 nCoV-19 also had risk of anaphylaxis/ anaphylactic reaction higher than mRNA vaccines. This vaccine also can cause the anaphylactic shock, anaphylactoid reaction and anaphylactoid shock. On the other hand, data from Korea concerning adverse events after vaccination of 998 healthcare workers showed that there was no cases of anaphylaxis after first dose of the ChAdOx1 nCoV-19 vaccine [40]. Among mRNA vaccines, the higher risk of anaphylaxis or anaphylactic reaction, anaphylactoid reaction as well as anaphylactic and anaphylactoid shocks occurred after BNT162b2 vaccine administration, especially in the EU. However, a report from Ontario in period between December 13, 2020 and March 6, 2021 noted anaphylaxis cases the rates of 32.7 and 38.0 per million doses

CDC COVID-19 Response Team (2021) 21.0 1893360 0 1893360 Hashimoto (2021) 204.2 100000 0 1000000 Shimabukuro (2021) 47.0 9943247 0 9943247 U 9943247 0 9943247 95.00 [ $5.86$ ; $5514.07$ ] 5. Klein (2021) 4.8 100000 0 1000000 EudraVigilance 5334.0 423878776 0 423878776 Public Health Agency of Canada 7.0 100000 0 1000000 Centers for Disease Control and Prevention 1027.0 470829872 0 470829872 Random effects model 909571184 909571184 Heterogeneity: $l^2 = 68\%$ , $\tau^2 = 4.4364$ , $p < 0.01$ mRNA-1273 vaccine Burmental (2021) 10.0 4041396 0 4041396 CDC COVID-19 Response Team (2021) 10.0 4041396 0 4041396 Shimabukuro (2021) 5.1 1000000 0 1000000 Cuctors for Disease Control and Prevention 651.0 310311408 0 310311408 Medicines & Healthcare products Regulatory Agency 14.8 1000000 0 1000000 Heterogeneity: $l^2 = 55\%$ , $\tau^2 = 2.5811$ , $p = 0.03$ Ad26.COV2.S vaccine EudraVigilance 104.0 15776597 0 15776597		Experimental		Control					
Binmental (2021) 7.0 25929 0 25929 CDC COVID-19 Response Team (2021) 210 1893360 0 1893360 CDC COVID-19 Response Team (2021) 204.2 1000000 0 1000000 Shimabukur (2021) 47.0 9943247 0 9943247 9 9943247 0 9943247 0 9943247 0 9943247 0 9943247 0 9943247 0 9943247 0 9943247 0 9943247 0 9943247 0 9943247 0 9943247 0 9943247 0 9943247 0 9943247 0 9943247 0 900000 0 1000000 Eudra Vigilance 5334.0 423878776 0 423878776 0 423878776 0 1000000 0 1000000 0 1000000 0 1000000	Study	Events	Total	Events	Total	Risk Ratio	RR	95%-CI	Weigh
$ \begin{array}{c} CDC COVID-19 (Response Team (2021) \\ Hashimoto (2021) \\ Hashimoto (2021) \\ Hashimoto (2021) \\ Chroson (2021) \\ Chroso$	BNT162b2 vaccine								
CDC COVID-19 Response Team (2021) 2014 21000000 0 1000000 Shimabukuro (2021) 47.0 9943247 0 10.05 (15.8 (1.0.0.5 (128.45, 328.367.49) 5.1 1000000 0 1000000 1 000000 0 1000000 0 1000000	Blumental (2021)	7.0	25929	0	25929		15.00	[ 0.86; 262.62]	4.99
Lashimoto (2021)204.2100000001000000Shimabukuro (2021)47.099432479943247Shimabukuro (2021)4.810000001000000Eudra Vigilance533.4.0423878776423878776Public Health Agency of Canada7.010000001000000Centers for Disease Control and Prevention1027.0470829872Random effects model90.571184909571184Heterogenety: $I^2 = 698_x, \tau^2 = 4.4364, p < 0.01$ 909571184mRNA-1273 vaccine90.3897138971Biumental (2021)9.038971CDC COV/D19 Response Team (2021)10.04041396CDC COV/D19 Response Team (2021)10.04041396CDC COV/D19 Response Team (2021)5.1Dubic Health Agency of Canada5.3Shimabukuro (2021)5.1Shimabukuro (2021)5.1Dubic Health Agency of Canada5.3Centers for Disease Control and Prevention65.10Budra Vigilance1254.0Public Health Agency of Canada5.3Adds COV2.5 vaccine386101754Eudra Vigilance104.0Eudra Vigilance104.0ChrAdOx1 nCoV-19 vaccine46392349Eudra Vigilance1220.0ChrAdOx1 nCoV-19 vaccineEudra Vigilance1220.0ChrAdOx1 ncoV-19 vaccineEudra Vigilance1220.0ChrAdOx1 ncoV-19 vaccineEudra Vigilance1220.0ChrAdOx1 ncoV-19 vaccineEudra VigilanceChra		21.0	1893360		1893360				5.0
Shimabukuro (2021)       47.0       9943247       0       9943247       99500       [5.56]       15.11.07]       5.5         Klein (2021)       48       1000000       0       1000000       1000000       10.66       [0.58]       122.57]       4.         Curles for Disease Control and Prevention       1027.0       470829872       0       470829872       10.668       0.665, 128.570       10.86, 25.500       128.64.31       5.5         Conters for Disease Control and Prevention       1027.0       470829872       0       470829872       10.668.0       11.11;       326.43;       4.         Buimental (2021)       9.0       38971       0       38971       38971       38971       10.068.0       10.86;       25.500       112.84,53;       5.3       5.3       1000000       1000000       10.00000       10.00000       10.00000       10.00000       10.00000       10.00000       11.00       1.11;       326.43,34       4.       4.41,20,43;       5.5       5.5       5.64; 15.41,97       5.5       5.64; 15.41,97       5.5       5.64; 15.24; 12.75; 4.       1.00; 12.23; 58.53; 12.25; 4.59; 2.52; 4.52; 327; 4.43; 5.5       5.5       5.5; 5.26; 11.27; 5.25; 4.52; 2.52; 4.52; 2.52; 4.5; 2.25; 4.52; 2.52; 4.52; 2.52; 4.52; 2.52; 4.52; 4.52; 4.52; 4.52; 4.52; 4.52; 4.52; 4.52; 4.52; 4.52; 4.52				Ő					5.1
Klein (2021) $(1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0,$				•					
EudraVigilance 5334.0 423878776 0 423878776 Public Health Agency of Canada 7.0 100000 0 100000 Centers for Disease Control and Prevention 1027.0 470829872 0 470829872 Sandom effects model 909571184 900500 112.35 (452852) 55. Shimabukuro (2021) 5.1 1000000 0 1000000 1000000 1000000 1000000				-					
Public Health Agency of Canada 7.0 1000000 0 1000000 Centers for Disease Control and Prevention 1027.0 470829872 0 470829872 9909571184 19.00 [1.117, 326.43] 51. CC COVL: 0.12.91 (2.35, 645.92] 52. Standow (2021) 5.1 1000000 0 1000000 0 1000000 0 1000000 0 1000000		=		•					
Centers for Disease Control and Prevention1027.0470829872 9095711840470829872 9095711840470829872 9095711840470829872 9095711840470829872 9095711840470829872 9095711840470829872 9095711840470829872 9095711840470829872 9095711840470829872 9095711840470829872 9095711840470829872 9095711840470829872 9095711840470829872 9095711840470829872 9095711840470829872 909571184900571184900571184900571184900571184900571184900571184900571184900571184900571854900571854900571855900571855900571855900571855900000001000000100000011.60[0.62, 202.11]414108253895.900575290000[1.296, 3363.59]5.90000[1.296, 3363.59]5.90000[1.299, 3363.59]5.900009000000 </td <td></td> <td></td> <td></td> <td>-</td> <td></td> <td></td> <td></td> <td></td> <td></td>				-					
Random effects model       909571184       909571184       909571184         Heterogeneity. $t^2 = 68\%, t^2 = 4.4364, p < 0.01$ 90.0       38971       0       38971         mRNA-1273 vaccine       3000       11.11;       326.43;       5.5         Shimabukuro (2021)       9.0       7581429       0       7581429         Scien (2021)       5.1       1000000       1000000       11.20;       0.62;       202.11]       4.2         EudraVigilance       1254.0       61128550       0       1128550       0       1128550         Public Health Agency of Canada       5.3       1000000       1000000       11.20;       0.62;       202.11]       4.2         Lenters for Disease Control and Prevention       651.0       310311408       310311408       310311408       1303.00;       [14.08;       280.82]       39.9         Adde. COV2. S vaccine       386101754       386101754       386101754       209.00;       [12.99;       336.359]       5.7         Cherds model       46392349       46392349       46392349       209.00;       [12.99;       336.359]       5.7         Condom effects model       46392349       46392349       46392349       209.00;       [12.99;       336.359]				•					
$\frac{1}{12} = 68\%, \tau^2 = 4.4364, p < 0.01$ $\frac{1}{112} = 68\%, \tau^2 = 4.4364, p < 0.01$ $\frac{1}{112} = 68\%, \tau^2 = 4.4364, p < 0.01$ $\frac{1}{112} = 68\%, \tau^2 = 4.4364, p < 0.01$ $\frac{1}{112} = 68\%, \tau^2 = 4.4364, p < 0.01$ $\frac{1}{112} = 68\%, \tau^2 = 4.4364, p < 0.01$ $\frac{1}{112} = 10, 0 = 1.11; 326, 43; 55; 100, 0 = 100, 000, 0 = 100, 000, 0 = 100, 000, 0$		1027.0		0					
$\begin{array}{c} nRNA-1273 \text{ vaccine} \\ nRNA-1273 \text{ vaccine} \\ Shimental (2021) & 9.0 & 38971 & 0 & 38971 \\ CDC COVID-19 Response Team (2021) & 10.0 & 4041396 & 0 & 4041396 \\ Shimental (2021) & 19.0 & 7581429 & 0 & 7581429 \\ Shimental (2021) & 5.1 & 1000000 & 0 & 1000000 \\ Such (2021) & 5.1 & 1000000 & 0 & 1000000 \\ Cherters for Disease Control and Prevention & 651.0 & 310311408 & 0 & 310311408 \\ Medicines & Healthcare products Regulatory Agency & 14.8 & 1000000 & 0 & 1000000 \\ Random effects model & 386101754 & 386101754 \\ telerogeneity: f^2 = 55\%, \tau^2 = 2.5811, p = 0.03 \\ \text{Ad26. COV2. S vaccine} \\ SudraVigilance & 104.0 & 15776597 & 0 & 15776597 \\ Charles for Disease Control and Prevention & 104.0 & 30615752 & 0 & 30615752 \\ Random effects model & 46392349 & 46392349 \\ telerogeneity: f^2 = 0\%, \tau^2 = 0, p = 1.00 \\ \text{ChAdOX1 n CoV-19 vaccine} \\ SudraVigilance & 1220.0 & 68794860 & 0 & 68794860 \\ O'Ubic Health Agency of Canada & 5.7 & 1000000 & 0 & 1000000 \\ Random effects model & 69794860 & 69794860 \\ telerogeneity: f^2 = 55\%, \tau^2 = 2.8854, p < 0.01 \\ \text{Random effects model} & 1411860147 & 1411860147 \\ \text{Teterogeneity: } f^2 = 59854, r^2 = 2.9854, p < 0.01 \\ \text{Random effects model} & 1411860147 & 1411860147 \\ \text{Teterogeneity: } f^2 = 59854, p < 0.01 \\ \text{Random effects model} & 1411860147 & 1411860147 \\ \text{Teterogeneity: } f^2 = 59854, p < 0.01 \\ \text{Random effects model} & 1411860147 & 1411860147 \\ \text{Teterogeneity: } f^2 = 59854, p < 0.01 \\ \text{Random effects model} & 1411860147 \\ \text{Teterogeneity: } f^2 = 59854, p < 0.01 \\ \text{Random effects model} & 1411860147 \\ Random effects$			909571184		909571184	$ \diamond$	133.93	[22.88; 783.90]	40.0
$\begin{array}{c} \text{Humental (2021)} & 9.0 & 38971 & 0 & 38971 \\ \text{DC C OVID-19 Response Team (2021)} & 10.0 & 4041396 \\ \text{Dimabukuro (2021)} & 19.0 & 7581429 \\ \text{Othimabukuro (2021)} & 5.1 & 1000000 & 0 & 1000000 \\ \text{Ludra Vigiliance} & 1254.0 & 61128550 & 61128550 \\ \text{Oublic Health Agency of Canada} & 5.3 & 1000000 & 0 & 1000000 \\ \text{Centers for Disease Control and Prevention} & 651.0 & 310311408 & 0 & 310311408 \\ \text{Redicines & Health Care products Regulatory Agency} & 14.8 & 1000000 & 0 & 1000000 \\ \text{Random effects model} & 386101754 \\ \text{Leter spenty: } f^2 = 55\%, t^2 = 2.5811, p = 0.03 \\ \text{Leter spenty: } f^2 = 55\%, t^2 = 0, p = 1.00 \\ \text{ChAdOX1 nCoV-19 vaccine} \\ \text{Ludra Vigiliance} & 1220.0 & 68794860 & 0 & 68794860 \\ \text{Chadox n effects model} & 5.7 & 1000000 & 0 & 1000000 \\ \text{Random effects model} & 5.7 & 1000000 & 0 & 1000000 \\ \text{Random effects model} & 5.7 & 1000000 & 0 & 1000000 \\ \text{Random effects model} & 5.7 & 1000000 & 0 & 1000000 \\ \text{Random effects model} & 5.7 & 1000000 & 0 & 1000000 \\ \text{Random effects model} & 5.7 & 1000000 & 0 & 1000000 \\ \text{Random effects model} & 5.7 & 1000000 & 0 & 1000000 \\ \text{Random effects model} & 5.7 & 1000000 & 0 & 1000000 \\ \text{Random effects model} & 5.7 & 1000000 & 0 & 1000000 \\ \text{Random effects model} & 5.7 & 1000000 & 0 & 1000000 \\ \text{Random effects model} & 5.7 & 1000000 & 0 & 1000000 \\ \text{Random effects model} & 5.7 & 1000000 & 0 & 1000000 \\ \text{Random effects model} & 5.7 & 1000000 & 0 & 1000000 \\ \text{Random effects model} & 5.7 & 1000000 & 0 & 1000000 \\ \text{Random effects model} & 5.7 & 1000000 & 0 & 10000000 \\ \text{Random effects model} & 5.7 & 1000000 & 0 & 10000000 \\ \text{Random effects model} & 1411860147 & 1411860147 \\ \text{Random effects model} & 1411860147 & 1411860147 \\ \text{Random effects model} & 106.99 & [39.95; 286.56] 100.4 \\ \text{Random effects model} & 106.99 & [39.95; 286.56] 100.4 \\ \text{Random effects model} & 106.99 & [39.95; 286.56] 100.4 \\ \text{Random effects model} & 106.99 & [39.95; 286.56] 100.4 \\ \text{Random effects model} & 106.99 & [39.95; 286.56] 100.4 \\ \text{Random effects model} &$	leterogeneity: $I^2 = 68\%$ , $\tau^2 = 4.4364$ , $p < 0.01$								
$ \begin{array}{c} 2000 \text{ VD} 19 \text{ Response Team (2021)} & 10.0 & 4041396 & 0 & 4041396 & 0 & 4041396 & 0 & 4041396 & 0 & 4041396 & 0 & 4041396 & 0 & 4041396 & 0 & 7581429 & 39.00 & [1.23] & 358.37] & 5.1 & 1000000 & 0 & 1000000 & 0 & 1000000 & 0 & $	nRNA-1273 vaccine								
$\frac{1220}{1223} = 2500 \text{ [} 1233 = 368.37] \text{ 5.}}{3200} = 2100 \text{ [} 1233 = 368.37] \text{ 5.}}{3200} = 2100 \text{ [} 1233 = 368.37] \text{ 5.}}{3200} = 2100 \text{ [} 1233 = 368.37] \text{ 5.}}{3200} = 2100 \text{ [} 1233 = 368.37] \text{ 5.}}{3200} = 2100 \text{ [} 1233 = 368.37] \text{ 5.}}{3200} = 2100 \text{ [} 1233 = 368.37] \text{ 5.}}{3200} = 2100 \text{ [} 1233 = 368.37] \text{ 5.}}{3200} = 2100 \text{ [} 1233 = 368.37] \text{ 5.}}{3200} = 2100 \text{ [} 1233 = 368.37] \text{ 5.}}{3200} = 2100 \text{ [} 1233 = 368.37] \text{ 5.}}{3200} = 2100 \text{ [} 1233 = 368.37] \text{ 5.}}{3200} = 2100 \text{ [} 1233 = 368.37] \text{ 5.}}{3200} = 2100 \text{ [} 1233 = 368.37] \text{ 5.}}{3200} = 2100 \text{ [} 1233 = 368.37] \text{ 5.}}{3200} = 2100 \text{ [} 1233 = 368.37] \text{ 5.}}{3200} = 2100 \text{ [} 1233 = 368.37] \text{ 5.}}{3200} = 2100 \text{ [} 1233 = 368.37] \text{ 5.}}{3200} = 2100 \text{ [} 1233 = 368.37] \text{ 5.}}{31000000} = 0 = 1000000 \text{ 0}}{1000000} = 1120 \text{ [} 0.65; = 208.47] \text{ 4.}}{32000} = 11.60 \text{ [} 0.65; = 208.47] \text{ 4.}}{32000} = 11.60 \text{ [} 0.65; = 208.47] \text{ 4.}}{32000} = 11.60 \text{ [} 0.65; = 208.47] \text{ 4.}}{32000} = 11.60 \text{ [} 12.99; = 3363.59] \text{ 5.}}{32000} = 11.60 \text{ [} 12.99; = 3363.59] \text{ 5.}}{32000} = 11.233 \text{ [} 14.08; = 280.82] \text{ 39.1}}{39.00} = 11.20 \text{ [} 12.99; = 3363.59] \text{ 5.}}{32000} = 11.20 \text{ [} 12.99; = 3363.59] \text{ 5.}}{3209.00} = 11.20 \text{ [} 12.99; = 3363.59] \text{ 5.}}{3209.00} = 11.20 \text{ [} 12.99; = 3363.59] \text{ 5.}}{3209.00} = 11.20 \text{ [} 12.99; = 3363.59] \text{ 5.}}{3209.00} = 12.99, 3363.59] \text{ 5.}}{3209.00} = 1220.0 \text{ 68794860} \text{ 68794860} \text{ 68794860} \text{ 69794860}  69794860$	Blumental (2021)	90	38971	0	38971		19 00	[ 1 11 <sup>-</sup> 326 43]	5.0
Shimabukuro (2021) 19.0 7581429 0 7581429 10.0 7581429 10.0 7581429 11.20 $[2.35, 645.92]$ 5.1 1000000 1000000 111.20 $[0.62, 202.11]$ 4.2 $[0.70, 221.21]$ 4.2 $[0.70, 221.21]$ 4.2 $[0.70, 221.21]$ 4.2 $[0.70, 221.21]$ 4.2 $[0.70, 221.21]$ 4.2 $[0.70, 221.21]$ 4.2 $[0.70, 221.21]$ 4.2 $[0.70, 221.21]$ 4.2 $[0.70, 221.21]$ 4.2 $[0.70, 221.21]$ 4.2 $[0.70, 221.21]$ 4.2 $[0.70, 221.21]$ 4.2 $[0.70, 221.21]$ 4.2 $[0.69, 794860]$ $[0.99, 7]$ 5.2 $[0.99, 7]$ 5.									5.0
Adein (2021)5.1100000001000000Ludra Vigilance1254.061128550061128550Public Health Agency of Canada5.3100000001000000Senters for Disease Control and Prevention651.03103114080310311408Medicines & Healthcare products Regulatory Agency14.8100000001000000Aradom effects model386101754386101754386101754Iderogeneity: $l^2 = 55\%$ , $\tau^2 = 2.5811$ , $p = 0.03$ 300157520300615752Adda effects model104.015776597015776597Control and Prevention104.030615752030615752Random effects model4639234946392349209.00[12.99; 3363.59]Leterogeneity: $l^2 = 0\%$ , $\tau^2 = 0$ , $p = 1.00$ 5.7100000001000000ChAdOx1 nCoV-19 vaccine1220.0687948606879486068794860Leterogeneity: $l^2 = 85\%$ , $\tau^2 = 11.8712$ , $p < 0.01$ 6979486069794860176.64Random effects model6979486069794860106.99[39.95; 286.56] 100.4Leterogeneity: $l^2 = 59\%$ , $\tau^2 = 2.9854$ , $p < 0.01$ 14118601471411860147106.99[39.95; 286.56] 100.4									
EudraVigilance 1254.0 61128550 0 61128550 100000 0 1000000 0 1000000 0 1000000 0 1000000				•					
Public Health Agency of Canada       5.3       1000000       0       1000000         Centers for Disease Control and Prevention       651.0       310311408       0       310311408       1303.00       [81.41, 20853.89]       5.         Andom effects model       14.8       1000000       1000000       30060       [1.83; 511.70]       5.         Audde COV2.S vaccine       386101754       386101754       386101754       62.88       [14.08; 280.82]       39.9         Vid26.COV2.S vaccine       104.0       15776597       0       15776597       209.00       [12.99; 3363.59]       5.         Centers for Disease Control and Prevention       104.0       30615752       0       30615752       209.00       [12.99; 3363.59]       5.         Conters for Disease Control and Prevention       104.0       30615752       0       30615752       209.00       [12.99; 3363.59]       5.         Leterogeneity: $l^2 = 0\%, \tau^2 = 0, p = 1.00$ 46392349       46392349       209.00       [152.60; 39047.67]       5.         ChAdOx1 nCoV-19 vaccine       1220.0       68794860       68794860       69794860       69794860       69794860       1000000       12.40       [0.70; 221.21]       4.         Leterogeneity: $l^2 = 85\%, \tau^2 = 11.8712, p < 0.01$				•					
Centers for Disease Control and Prevention $651.0$ $310311408$ $0$ $310311408$ $0$ $310311408$ $1303.00$ $[81.41; 20853.89]$ $5.$ Letter ogeneity: $l^2 = 55\%$ , $\tau^2 = 2.5811$ , $p = 0.03$ $14.8$ $1000000$ $0$ $1000000$ $30.60$ $[1.83; 511.70]$ $5.$ Letter ogeneity: $l^2 = 55\%$ , $\tau^2 = 2.5811$ , $p = 0.03$ $386101754$ $386101754$ $386101754$ $62.88$ $[14.08; 280.82]$ $39.36$ Letter ogeneity: $l^2 = 55\%$ , $\tau^2 = 2.5811$ , $p = 0.03$ $104.0$ $15776597$ $0$ $15776597$ $0$ $15776597$ Letter ogeneity: $l^2 = 0\%$ , $\tau^2 = 0$ , $p = 1.00$ $104.0$ $30615752$ $0$ $30615752$ $209.00$ $[12.99; 3363.59]$ $5.$ Letter ogeneity: $l^2 = 0\%$ , $\tau^2 = 0$ , $p = 1.00$ $46392349$ $46392349$ $46392349$ $209.00$ $[29.30; 1490.67]$ $10.1000000$ ChAdOx1 n CoV-19 vaccine $1220.0$ $68794860$ $0$ $68794860$ $0$ $68794860$ $12.40$ $[152.60; 39047.67]$ $5.$ Leter ogeneity: $l^2 = 85\%$ , $\tau^2 = 11.8712$ , $p < 0.01$ $69794860$ $69794860$ $69794860$ $12.40$ $[1.00; 31280.66]$ $10.1000000$ Leter ogeneity: $l^2 = 85\%$ , $\tau^2 = 2.9854$ , $p < 0.01$ $1411860147$ $1411860147$ $1411860147$ $106.99$ $[39.95; 286.56]$ $100.1000000$				-					
Medicines & Healthcare products Regulatory Agency       14.8       1000000       0       1000000         Random effects model       386101754       386101754       386101754         Ideterogeneity: $l^2 = 55\%, \tau^2 = 2.5811, p = 0.03$ 104.0       15776597       0       15776597         Value COV2.S vaccine       104.0       15776597       0       15776597         Centers for Disease Control and Prevention       104.0       30615752       0       30615752         Random effects model       46392349       46392349       209.00       [12.99; 3363.59]       5.         Valic Leatin Agency of Canada       5.7       1000000       0       1000000       1000000         Random effects model       5.7       1000000       0       1000000       1000000         Iteterogeneity: $l^2 = 85\%, \tau^2 = 11.8712, p < 0.01$ 1411860147       1411860147       1411860147				•					
Random effects model       386101754       386101754       386101754       386101754       386101754       62.88 $[14.08; 280.82]$ 39.4         Ad26. COV2. S vaccine       104.0       15776597       0       15776597       209.00 $[12.99; 3363.59]$ 5.         Centers for Disease Control and Prevention       104.0       30615752       0       30615752       209.00 $[12.99; 3363.59]$ 5.         Random effects model       46392349       46392349       46392349       209.00 $[12.99; 3363.59]$ 5.         ChAdOx1 n CoV-19 vaccine       1220.0       68794860       0       68794860       2441.00 $[152.60; 39047.67]$ 5.         Dublic Heatth Agency of Canada       5.7       1000000       0       1000000       12.40 $[0.70; 221.21]$ 4.         Random effects model       69794860       69794860       69794860       69794860       106.99 $[39.95; 286.56]$ 100.4         Heterogeneity: $l^2 = 85\%, r^2 = 2.9854, p < 0.01$ 1411860147       1411860147       1411860147       106.99 $[39.95; 286.56]$ 100.4				-					
Heterogeneity: $l^2 = 55\%$ , $\tau^2 = 2.5811$ , $p = 0.03$ Ad26. COV2.S vaccine         Eudra Vigilance         Centers for Disease Control and Prevention         104.0       15776597         Centers for Disease Control and Prevention         104.0       30615752         Random effects model         LudraVigilance       104.0         EudraVigilance       104.0         ChAdOX1 nCoV-19 vaccine         EudraVigilance       1220.0         Bubic Health Agency of Canada         Random effects model       68794860         Heterogeneity: $l^2 = 85\%$ , $\tau^2 = 11.8712$ , $p < 0.01$ Random effects model       69794860         Heterogeneity: $l^2 = 2.9854$ , $p < 0.01$		/ 14.8		0				[ 1.83; 511.70]	5.0
Ad26. COV2. S vaccine         Eudra Vigilance       104.0       15776597       0       15776597         Centers for Disease Control and Prevention       104.0       30615752       0       30615752         Random effects model       46392349       46392349       209.00       [12.99; 3363.59] 5.         ChAdOx1 nCoV-19 vaccine       209.00       [29.30; 1490.67] 10.         Eudra Vigilance       1220.0       68794860       0       68794860         Public Health Agency of Canada       5.7       1000000       1000000       12.40       [0.70; 221.21] 4.         Random effects model       69794860       69794860       106.99       [39.95; 286.56] 100.4         Heterogeneity: $l^2 = 59\%$ , $\tau^2 = 2.9854$ , $p < 0.01$ 1411860147       1411860147       106.99       [39.95; 286.56] 100.4			386101754		386101754		62.88	[14.08; 280.82]	39.9
Eudra Vigilance       104.0       15776597       0       15776597       209.00       [12.99; 3363.59]       5.         Centers for Disease Control and Prevention       104.0       30615752       0       30615752       209.00       [12.99; 3363.59]       5.         Random effects model       46392349       46392349       46392349       209.00       [12.99; 3363.59]       5.         ChAdOx1 n CoV-19 vaccine       1220.0       68794860       0       68794860       209.000       [152.60; 39047.67]       5.         Public Health Agency of Canada       5.7       1000000       0       10000000       12.40       [0.70; 221.21]       4.         Random effects model       69794860       69794860       69794860       176.64       [1.00; 31280.66]       10.         Heterogeneity: $l^2 = 89\%$ , $t^2 = 11.8712$ , $p < 0.01$ 1411860147       1411860147       106.99       [39.95; 286.56]       100.0	Heterogeneity: $I^2 = 55\%$ , $\tau^2 = 2.5811$ , $p = 0.03$								
Centers for Disease Control and Prevention       104.0 $30615752$ 0 $30615752$ 209.00 $[12.99]', 3363.59]', 5.$ Random effects model       46392349       46392349       46392349       209.00 $[29.30]; 1490.67]', 10.7$ ChAdOx1 nCoV-19 vaccine       1220.0       68794860       0       68794860       2441.00 $[152.60]; 39047.67]', 5.$ Public Health Agency of Canada       5.7       1000000       0       1000000       12.40 $[0.70]; 221.21]', 4.$ Random effects model       69794860       69794860       69794860       1000000         Heterogeneity: $l^2 = 85\%, r^2 = 11.8712, p < 0.01$ 1411860147       1411860147       106.99 $[39.95]; 286.56]$ 100.4	Ad26.COV2.S vaccine								
Random effects model       46392349       46392349       209.00       [29.30]; 1490.67]       10.         teterogeneity: $l^2 = 0\%, \tau^2 = 0, p = 1.00$ 209.00       [29.30]; 1490.67]       10.         ChAdOx1 nCoV-19 vaccine       1220.0       68794860       0       68794860       1000000         Vubic Health Agency of Canada       5.7       1000000       0       1000000       12.40       [152.60]; 39047.67]       5.         Random effects model       69794860       69794860       69794860       100.1000000       100.0000         Random effects model       69794860       69794860       106.99       [39.95]; 286.56] 100.4         teterogeneity: $l^2 = 59\%, \tau^2 = 2.9854, p < 0.01$ 1411860147       1411860147       106.99       [39.95]; 286.56] 100.4	EudraVigilance	104.0	15776597	0	15776597		209.00	[ 12.99; 3363.59]	5.1
Random effects model       46392349       46392349       209.00 $[29.30]$ ; 1490.67]       10.         leterogeneity: $I^2 = 0\%, \tau^2 = 0, p = 1.00$ 209.00 $[29.30]$ ; 1490.67]       10.         ChAdOx1 nCoV-19 vaccine       1220.0       68794860       0       68794860       1000000         ChAdOx1 nCoV-19 vaccine       1220.0       68794860       0       68794860       1000000         Sandom effects model       69794860       69794860       69794860       1000000         leterogeneity: $I^2 = 85\%, \tau^2 = 11.8712, p < 0.01$ 1411860147       1411860147       106.99       [39.95; 286.56] 100.0		104.0	30615752	0	30615752		209.00		5.1
leterogeneity: $l^2 = 0\%$ , $\tau^2 = 0$ , $p = 1.00$ ChAdOX1 nCoV-19 vaccine         LudraVigilance       1220.0       68794860       0       68794860         LudraVigilance       1220.0       68794860       0       1000000         LudraVigilance       1220.0       68794860       0       68794860         LudraVigilance       1220.0       68794860       0       1000000         Random effects model       69794860       69794860       176.64       [ 1.00; 31280.66] 10.0         Random effects model       1411860147       1411860147       106.99       [ 39.95; 286.56] 100.0								. , , ,	
EudraVigilance       1220.0 $68794860$ 0 $68794860$ 0 $68794860$ 0 $1000000$ 0       1000000       12.40 $[0.70; 221.21]$ 4.         Public Health Agency of Canada $5.7$ $1000000$ $0$ $1000000$ $12.40$ $[0.70; 221.21]$ $4.$ Leterogeneity: $l^2 = 85\%, \tau^2 = 11.8712, p < 0.01$ 1411860147       1411860147       106.99 $[39.95; 286.56]$ $100.0000$ Leterogeneity: $l^2 = 59\%, \tau^2 = 2.9854, p < 0.01$ 1411860147       1411860147 $106.99$ $[39.95; 286.56]$ $100.0000$			40002040		40002040		200.00	[20.00, 1400.01]	10.1
tudraVigilance       1220.0 $68794860$ 0 $68794860$ 0 $2441.00$ $[152.60; 39047.67]$ 5.         tublic Health Agency of Canada       5.7       1000000       0       1000000       12.40 $[0.70; 221.21]$ 4.         tandom effects model       69794860       69794860       69794860       69794860       100.0000       1000000         tandom effects model       1411860147       1411860147       1411860147       106.99       [39.95; 286.56] 100.0000	hAdox1 nCoV-19 vaccine								
Public Health Agency of Canada       5.7       1000000       0       1000000         Random effects model       69794860       69794860       69794860         Ideterogeneity: $l^2 = 85\%$ , $\tau^2 = 11.8712$ , $p < 0.01$ 1411860147       1411860147         Random effects model       1411860147       1411860147		1220.0	68794860	0	68794860		2441.00	[152 60 39047 67]	5 1
Random effects model       69794860       69794860       176.64       [1.00; 31280.66] 10.0         leterogeneity: $I^2 = 85\%$ , $\tau^2 = 11.8712$ , $p < 0.01$ 1411860147       1411860147       106.99       [39.95; 286.56] 100.0         leterogeneity: $I^2 = 59\%$ , $\tau^2 = 2.9854$ , $p < 0.01$ 1411860147       1411860147       106.99       [39.95; 286.56] 100.0				-				. , , , ,	
leterogeneity: $l^2 = 85\%$ , $\tau^2 = 11.8712$ , $p < 0.01$ Random effects model         1411860147         1411860147         106.99         [39.95; 286.56] 100.1		5.7		0					
Random effects model 1411860147 1411860147 $\diamond$ 106.99 [39.95; 286.56] 100.0 leterogeneity: $l^2 = 59\%$ , $\tau^2 = 2.9854$ , $p < 0.01$			09794860		09/94860		170.64	[ 1.00; 31280.66]	10.0
leterogeneity: $l^2 = 59\%$ , $\tau^2 = 2.9854$ , $p < 0.01$	leterogeneity: $I^{-} = 85\%$ , $\tau^{-} = 11.8712$ , $p < 0.01$								
			1411860147		1411860147	&	106.99	[ 39.95; 286.56]	100.0
est for subgroup differences: $\chi_2^2 = 1.03$ , df = 3 (p = 0.79) 0.001 0.1 1 10 1000						1 1 1 1 1			
	est for subgroup differences: $\chi_3^2 = 1.03$ , df = 3 (p = 0.7)	9)				0.001 0.1 1 10 1000			





administered of mRNA-1273 and BNT162b2, respectively [41]. Among health care providers from Baylor Scott and White Health from Texas, which were vaccinated with first dose, only 3 persons had anaphylaxis what corresponds to 0.01% of vaccinated medical staff members [42]. In overall, in U.S. after first month of vaccination in period between December 14, 2020 and January 13, 2021, 4.5 per million cases of anaphylaxis after doses administered of both mRNA vaccines have been reported [43].

Considering potential causes of anaphylaxis reactions after COVID-19 vaccine administration, one can think of the vaccine component, such as polyethylene glycol (PEG2000), which is contained in mRNA vaccines— BNT162b2 and mRNA-1273, while viral vector vaccines (ChAdOx1 nCoV-19 and Ad26.COV2.S) contain polyethylene glycol derivatives, called polysorbate 80 [44, 45]. Polyethylene glycols are group of polymers, which are formed from ethylene oxide during the polymerization reaction. These polyether compounds are used in different industry, such as cosmetics, medicine, household products and food. The pegylation of drugs may increase the circulation time, because of drug protection from immune degradation as well as metabolism. In case of mRNA COVID-19 vaccines, pegylated nanoparticles can protect mRNA against enzymatic degradation increasing its stability [45, 46]. Moreover, mRNA may bind to PAMP (pathogen-associated molecular pattern) receptors as well as activate contact system protein, which in turn, can lead to anaphylactoid reactions. This is another reason, why mRNA COVID-19 vaccines are encapsulated into nanoparticles [39]. The mechanism of hypersensitivity reactions against PEG is not fully understood. Studies showed that IgM and IgG antibodies can form against PEG in humans, which for the first time was reported in 2005 in trials of Pegloticase. Similar effect was observed after administration of PEG asparaginase used in chemotherapy [39]. These formed IgG and IgM antibodies can activate complement as well as release the mediators, which is called complement activation-related pseudoallergy (CAPRA). In addition to the above, PEG may induce the formation of IgE antibodies [46]. In Singapore in April 2021, there were 20 cases of anaphylaxis after 2 213 888 doses of BNT162b2 and mRNA-1273 vaccines. Among these cases, Lim XR et al. [47] analyzed anti-BNT162b2 and anti-PEG antibodies for 3 patients. They detected IgG and IgM antibodies against BNT162b2 vaccine in all samples, as well as the higher level of IgG and IgM against PEG in 2 samples. However, IgE antibodies against BNT162b2 vaccine were not detected, from which it can be concluded that these cases of anaphylaxis were examples of CAPRA, not of typical allergic reaction. Due to the small number of studied patients, it cannot be concluded that this mechanism alone is responsible for the development of anaphylaxis after BNT162b2 vaccine.

In contrast to PEG, polysorbates are components of many used vaccines and medicines including monoclonal antibodies as well as biological agents. Because these PEG derivatives have less molecular weight than PEG, they are less likely to cause allergic reactions. Although, there are reports of anaphylaxis caused by polysorbates in animal models via IgE-independent mechanism, but not much cases were reported in humans [45]. Interesting case of biphasic anaphylaxis was reported after vaccination with first dose of BNT162b2 vaccine. After skin and intradermal testing, the patient was found to be negative for PEG, but different results for drugs containing polysorbate 80, which is not present in the BNT162b2 vaccine: skin test for triamcinolone acetonide was negative, but intradermal test was positive, then test for Prevnar-13 was negative, but for Refresh sterile eye drops was positive. Additionally, the test for BNT162b2 vaccine was also negative. The authors suggested that the particular case of anaphylaxis arose from a cross-reaction of PEG and polysorbate 80, however negative results of skin tests for PEG as well as methylprednisolone do not support this suggestion. The reason for such discrepancies may be the low concentration of PEG needed to bring on positive

The crucial point in anaphylaxis reaction after COVID-19 vaccination is correct and quick management after vaccine administration. According to Centers for Disease Control and Prevention [25] recommendations on anaphylaxis management after COVID-19 vaccines, at the vaccination sites the qualified healthcare personnel who could identify the symptoms and administer the epinephrine should be available. Moreover, recommended observation time after vaccination equals 15 min, but it is extended to 30 min for people with a history of anaphylaxis induced by any cause or an immediate allergic reaction to other vaccine or injectable therapy as well as for people with a contraindication to other types of COVID-19 vaccines. If anaphylaxis is suspected, breathing, airway, circulation and mental activity of patient should be assessed and emergency medical services should be immediately contacted. Next, the patient should be place in a supine position. The first-line drug, epinephrine, should be administered intramuscularly in dose 0.3 mg with maximum dose 0.5 mg every 5–15 min.

In summary, our meta-analysis showed that all authorized COVID-19 vaccines may cause anaphylactic reaction, anaphylactoid reaction, anaphylactic shock, and anaphylactoid shock. However, our study has several limitations. First, in the study, we used data from reports as well as databases, and updates of data in databases is not well-coordinated. Second, not all anaphylaxis cases may have been reported correctly and timely. All this may have resulted in a slight deviation of our calculations from reality. In addition, we included all reports in our analysis, not just those assessed by the Brighton criteria.

## Conclusion

test reaction [48].

Allergic reaction, especially anaphylaxis, may be a serious problem in COVID-19 vaccination process. Therefore, it is important to acknowledge the risk factors predisposing to the anaphylaxis caused by vaccination. Of note, in case of administration of any up-to-date registered COVID-19 vaccines, proper anaphylaxis precautions as well as adequately trained medical staff are required.

Acknowledgements Not applicable.

## Authors' contributions

MS searched the literature and databases, prepared the analysis, interpreted the results, and wrote the manuscript; RP supervised the overall study, analyzed the data and critically reviewed the manuscript. All the authors have read and approved the final manuscript.

#### Funding

This work was supported by Grants [503/0-149-03/503-01-001-19-00; 503/0-149-03/503-01-004 and 503/0-149-03/503-01-005] from Medical University of Lodz.

## Availability of data and materials

All data generated or analyzed during this study are included in this published article.

## Declarations

**Ethics approval and consent to participate** Not applicable.

## **Consent for publication**

Not applicable.

#### **Competing interests**

The authors declare that they have no competing interests.

Received: 12 November 2021 Accepted: 6 January 2022 Published online: 17 January 2022

#### References

- Hofman K, Shenoy GN, Chak V, Balu-Iyer SV. Pharmaceutical aspects and clinical evaluation of COVID-19 vaccines. Immunol Invest. 2021. https:// doi.org/10.1080/08820139.2021.1904977.
- WHO Coronavirus (COVID-19) Dashboard. 2021. https://covid19.who.int. Accessed 30 Oct 2021.
- Home ClinicalTrials.gov. 2021. https://clinicaltrials.gov/ct2/home. Accessed 30 Oct 2021.
- European Medicines Agency [Internet]. European Medicines Agency. 2021. https://www.ema.europa.eu/en. Accessed 30 Oct 2021.
- Frenck RW, Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, et al. Safety, immunogenicity, and efficacy of the BNT162b2 covid-19 vaccine in adolescents. N Engl J Med. 2021. https://doi.org/10.1056/NEJMoa2107 456.
- Chu L, McPhee R, Huang W, Bennett H, Pajon R, Nestorova B, et al. A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. Vaccine. 2021;39(20):2791–9.
- Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15.
- Commissioner O of the. U.S. Food and Drug Administration. FDA. FDA; 2021. https://www.fda.gov/home. Accessed 30 Oct 2021.
- Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403–16.
- Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, et al. Efficacy of the ChAdOx1 nCoV-19 covid-19 vaccine against the B.1.351 variant. N Engl J Med. 2021;384(20):1885–98.
- Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2020;396(10267):1979–93.
- 12. Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, et al. Interim results of a phase 1–2a trial of Ad26.COV2.S covid-19 vaccine. N Engl J Med. 2021. https://doi.org/10.1056/NEJMoa2034201.

- Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against covid-19. N Engl J Med. 2021. https://doi.org/10.1056/NEJMoa2101544.
- Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111.
- Emary KRW, Golubchik T, Aley PK, Ariani CV, Angus B, Bibi S, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet. 2021;397(10282):1351–62.
- Rehman SU, Rehman SU, Yoo HH. COVID-19 challenges and its therapeutics. Biomed Pharmacother. 2021;142: 112015.
- McNeil MM, Weintraub ES, Duffy J, Sukumaran L, Jacobsen SJ, Klein NP, et al. Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol. 2016;137(3):868–78.
- LoVerde D, Iweala OI, Eginli A, Krishnaswamy G. Anaphylaxis. Chest. 2018;153(2):528–43.
- Brown SGA. Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol. 2004;114(2):371–6.
- 20. Tupper J, Visser S. Anaphylaxis. Can Fam Physician. 2010;56(10):1009–11.
- 21. Reber LL, Hernandez JD, Galli SJ. The pathophysiology of anaphylaxis. J Allergy Clin Immunol. 2017;140(2):335–48.
- 22. Lagopoulos V, Gigi E. Anaphylactic and anaphylactoid reactions during the perioperative period. Hippokratia. 2011;15(2):138–40.
- 23. European database of suspected adverse drug reaction reports. 2021. https://www.adrreports.eu/. Accessed 20 Oct 2021.
- 24. Homepage | European centre for disease prevention and control. 2021. https://www.ecdc.europa.eu/en. Accessed 20 Oct 2021.
- CDC. CDC Works 24/7. Centers for disease control and prevention. 2021. https://www.cdc.gov/index.htm. Accessed 20 Oct 2021.
- Canada PHA of. COVID-19 vaccine safety: weekly report on side effects following immunization. aem. 2021. https://health-infobase.canada.ca/ covid-19/vaccine-safety/. Accessed 20 Oct 2021.
- Coronavirus vaccine—weekly summary of Yellow Card reporting. GOV. UK. 2021. https://www.gov.uk/government/publications/coronaviruscovid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-ofyellow-card-reporting. Accessed 21 Oct 2021.
- Moher D, Liberati A, Tetzlaff J, Altman DG, Group TP. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Med. 2009;6(7): e1000097.
- Deeks JJ, Higgins JP, Altman DG. Analysing data and undertaking meta-analyses. In: Higgins JP, Green S, editors. Cochrane handbook for systematic reviews of interventions. Chichester: Wiley; 2008. p. 243–96.
- Hashimoto T, Ozaki A, Bhandari D, Sawano T, Sah R, Tanimoto T. High anaphylaxis rates following vaccination with the Pfizer BNT162b2 mRNA vaccine against COVID-19 in Japanese healthcare workers: a secondary analysis of initial post-approval safety data. J Travel Med. 2021. https://doi. org/10.1093/jtm/taab090.
- Blumenthal KG, Robinson LB, Camargo CA, Shenoy ES, Banerji A, Landman AB, et al. Acute allergic reactions to mRNA COVID-19 vaccines. JAMA. 2021;325(15):1562–5.
- Klein NP, Lewis N, Goddard K, Fireman B, Zerbo O, Hanson KE, et al. surveillance for adverse events after COVID-19 mRNA vaccination. JAMA. 2021;326(14):1390–9.
- Shimabukuro TT, Cole M, Su JR. Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US—December 14, 2020-January 18, 2021. JAMA. 2021;325(11):1101–2.
- CDC COVID-19 Response Team, Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine—United States, December 21, 2020–January 10, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(4):125–9.
- CDCMMWR. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine—United States, December 14–23, 2020. MMWR Morb Mortal Wkly Rep. 2021. https://doi.org/10. 15585/mmwr.mm7002e1.
- Lee E, Lee Y, Kim TE, Hwang I, Jung YH, Lee HR, et al. Reports of anaphylaxis after coronavirus disease 2019 vaccination, South Korea, 26 February to 30 April 2021. Eurosurveillance. 2021;26(33):2100694.
- Iguchi T, Umeda H, Kojima M, Kanno Y, Tanaka Y, Kinoshita N, et al. Cumulative adverse event reporting of anaphylaxis after mRNA COVID-19

vaccine (Pfizer-BioNTech) injections in Japan: the first-month report. Drug Saf. 2021. https://doi.org/10.1007/s40264-021-01104-9.

- Eaddy Norton A, Broyles AD. Drug allergy in children and adults. Ann Allergy Asthma Immunol. 2019;122(2):148–55.
- Risma KA, Edwards KM, Hummell DS, Little FF, Norton AE, Stallings A, et al. Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines. J Allergy Clin Immunol. 2021;147(6):2075-2082.e2.
- Song JE, Oh G-B, Park HK, Lee S-S, Kwak YG. Survey of adverse events after the first dose of the ChAdOx1 nCoV-19 vaccine: a single-center experience in Korea. Infect Chemother. 2021;53(3):557–61.
- 41. Reports of events managed as anaphylaxis following COVID-19 vaccines in Ontario: December 13, 2020 to March 6, 2021. 2020;11.
- Arroliga ME, Dhanani K, Arroliga AC, Huddleston PS, Trahan J, Aguilar T, et al. Allergic reactions and adverse events associated with administration of mRNA-based vaccines. A health-care system experience. Allergy Asthma Proc. 2021;42(5):395–9.
- Gee J, Marquez P, Su J, Calvert GM, Liu R, Myers T, et al. First month of COVID-19 vaccine safety monitoring—United States, December 14, 2020–January 13, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(8):283–8.
- 44. Kim M-A, Lee YW, Kim SR, Kim J-H, Min T, ki, Park H-S, et al. COVID-19 vaccine-associated anaphylaxis and allergic reactions: consensus statements of the KAAACI Urticaria/Angioedema/Anaphylaxis Working Group. Allergy Asthma Immunol Res. 2021;13(4):526–44.
- Turner PJ, Ansotegui IJ, Campbell DE, Cardona V, Ebisawa M, El-Gamal Y, et al. COVID-19 vaccine-associated anaphylaxis: a statement of the World Allergy Organization Anaphylaxis Committee. World Allergy Organ J. 2021;14(2): 100517.
- Erdeljic Turk V. Anaphylaxis associated with the mRNA COVID-19 vaccines: approach to allergy investigation. Clin Immunol. 2021;227: 108748.
- Lim XR, Leung BP, Ng CYL, Tan JWL, Chan GYL, Loh CM, et al. Pseudoanaphylactic reactions to Pfizer BNT162b2 vaccine: report of 3 cases of anaphylaxis post Pfizer BNT162b2 vaccination. Vaccines. 2021;9(9):974.
- Pitlick MM, Park MA, Gonzalez-Estrada A, Chiarella SE. Biphasic anaphylaxis after first dose of messenger RNA coronavirus disease 2019 vaccine with positive polysorbate 80 skin testing result. Ann Allergy Asthma Immunol. 2021;127(4):498–9.

## **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

#### Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

#### At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

